TB-500 Safety Signals and FDA Actions: What Patients and Clinicians Need to Know

What TB-500 Is and Is Not

TB-500 is commonly identified as the N-terminal-acetylated seven-amino-acid peptide Ac-LKKTETQ, corresponding to residues 17 through 23 of the naturally occurring 43-amino-acid peptide thymosin beta-4 [1,2].

The two names are often blurred online, but TB-500 and full-length thymosin beta-4 are different substances. That distinction changes how evidence should be read:

• Cell and animal studies of full-length thymosin beta-4 do not establish the effects of TB-500.
• Human eye, cardiac, or wound studies of a pharmaceutical full-length product do not establish the safety of an injected TB-500 fragment.
• A biological mechanism proposed for the parent peptide is not proof that the fragment produces the same effect in a person.

FDA also found ambiguity in the nomination it reviewed: the information did not consistently identify TB-500 free base versus TB-500 acetate, which are different active pharmaceutical ingredients. Neither evaluated substance has an applicable USP or National Formulary monograph, and neither is a component of an FDA-approved drug [1].

FDA’s current evidence review

For the July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting, FDA prepared a detailed assessment of TB-500 free base and TB-500 acetate for wound healing. FDA reported that it did not find:

• studies in which TB-500 was administered to human patients
• human pharmacokinetic or pharmacodynamic studies
• clinical evidence of wound-healing effectiveness
• clinical studies assessing immunogenicity or aggregation
• nonclinical toxicology studies adequate to inform human safety
• in-vivo nonclinical evidence that the evaluated TB-500 substances promote wound healing

FDA did identify an in-vitro scratch-wound experiment in which the parent TB-500 substance did not produce wound healing under the studied conditions, although one metabolite showed an in-vitro signal. That laboratory observation is not clinical evidence and does not establish that a person’s tendon, muscle, ligament, surgical wound, or skin wound will heal faster [1].

What about the new trial registration?

ClinicalTrials.gov lists a recruiting study of TB-500 and cardiovascular biomarkers in adults ages 40 to 75. The record was first posted March 23, 2026, has no posted results, excludes adolescents, and states that the studied drug product is not U.S. FDA-regulated [3].

A registry entry is not a favorable result, approval, or recommendation. Until validated results exist, it cannot supply a side-effect rate or support dosing for wound healing or sports injuries.

The actual TB-500 safety signals

“Safety signal” can mean an observed pattern of adverse events. For TB-500, the defining problem is that there is not a reliable exposed population or adverse-event dataset from which to calculate a pattern.

FDA searched its Adverse Event Reporting System through March 26, 2025 and retrieved no reports. Its literature search found no human adverse-event cases. A separate FDA complaint-system search found two reports referring to a blended TB-500/BPC-157 product, but those reports did not contain safety assessments [1].

Those findings cannot be converted into “no risk.” FDA specifically noted that:

• adverse-event reporting is voluntary in this context
• FDA does not receive every event, especially for compounded products
• product names may be ambiguous
• there may be no certainty that a reported reaction was caused by the suspected product

Therefore, claims such as “injection-site redness occurs in 10% to 15%,” “serious effects are rare,” or “four to six weeks is safe” are not supported by a denominated human dataset. The type, frequency, dose relationship, and long-term risk of adverse effects remain unknown.

FDA’s product-quality and immune-response concerns

Chemical identity and impurities

Synthetic peptide manufacturing can produce truncated sequences, deletion products, stereoisomers, residual reagents or solvents, and aggregates. FDA found that a representative certificate of analysis discussed in its review did not control or report all clinically important attributes: assay, individual impurities, bacterial endotoxins, and aggregates were not fully tested or controlled [1].

A certificate of analysis is useful only for the attributes actually measured, using appropriate validated methods, on the relevant lot. “99% purity” does not establish sterility, identity of every impurity, potency of the finished vial, endotoxin limits, or clinical safety.

Aggregation and immunogenicity

Peptides can aggregate, and aggregation can alter bioavailability and increase the risk of immune responses. FDA explained that injected peptides can cause immune reactions ranging from antibodies without obvious symptoms to severe, unpredictable reactions. Peptide-related impurities may add to that risk [1].

This is a plausible product-class and formulation concern, not a measured TB-500 incidence. No clinical study has established how often it occurs with TB-500 or whether one marketed form is safer than another.

Sterility and endotoxin

An injectable product also has to be sterile and appropriately controlled for bacterial endotoxins. Contamination can cause a local infection, abscess, bloodstream infection, or severe inflammatory response. Endotoxin can remain hazardous even when no live bacteria are present.

FDA emphasizes that compounded drugs are not FDA-approved and are not reviewed for safety, effectiveness, or quality before marketing. Poor compounding practices can lead to contamination or incorrect strength and can cause serious injury or death [4].

Online and mislabeled products

Products sold as “research use only” are not approved medicines for self-injection. Online naming is especially unreliable because sellers may use TB-500, thymosin beta-4, TB4 fragment, free base, and acetate inconsistently.

In a 2023 analytical report, investigators characterized online products sold as TB500/TB1000 and SGF1000 as misbranded or adulterated [5]. That does not establish the contents of every vial, but it demonstrates why a website label or seller-provided document cannot be treated as proof of identity.

Do not assume that:

• a product contains the peptide named on the label
• the amount in the vial matches the stated strength
• “research grade” means suitable for injection
• a pharmacy, clinic, or telehealth label means FDA-approved
• a prescription eliminates formulation and evidence gaps

Cancer and angiogenesis: what can honestly be said

Online discussions often claim either that TB-500 “causes cancer” or that it has been proven cancer-safe. Neither statement is supported by human TB-500 data.

Some full-length thymosin beta-4 and cell-model studies discuss angiogenesis, migration, inflammation, and tumor biology. They may generate scientific questions, but they do not establish that injected TB-500 causes, accelerates, prevents, or has no effect on human cancer.

There is no validated TB-500 cancer-screening protocol. Routine scans, tumor markers, or extra screening solely because someone is considering TB-500 have not been shown to make its use safe. People should continue age- and risk-appropriate cancer screening and discuss any personal cancer history with their own clinician, but “screen first, then use TB-500” is not an evidence-based safety strategy.

FDA actions and compounding status

Prior category-2 safety concerns

FDA’s compounding-risk page identifies thymosin beta-4 fragment (LKKTETQ), also known as TB-500, among previously nominated substances for which the agency identified potential significant safety concerns, including aggregation, peptide-related impurities, immunogenicity, and absent human-exposure data [6].

The nomination discussed in the 2026 briefing had been withdrawn. FDA nevertheless evaluated TB-500 free base and acetate on its own initiative because of continued uncertainty about the substance and proposed use [1].

July 2026 advisory vote

FDA staff recommended against placing TB-500 free base or acetate on the section 503A bulk drug substances list. Staff cited inadequate physicochemical characterization, unclear historical compounding use, no human effectiveness or safety evidence, and potential immunogenicity [1].

On July 23, 2026, the outside advisory committee voted 8 to 6, with one abstention, to recommend inclusion for wound healing [7,8]. The vote did not:

• approve TB-500
• establish that TB-500 is safe or effective
• create an FDA-reviewed product label
• validate athletic recovery, bodybuilding, anti-aging, pediatric, or combination use
• set a lawful universal pathway for every seller or compounder
• complete FDA’s final determination or rulemaking

FDA’s meeting materials state that it would consider committee input before making a final determination [7]. A compounded drug and an FDA-approved drug remain different regulatory categories.

Warning letters need precise interpretation

FDA has issued warning letters involving peptide sellers and compounders, but a letter about full-length thymosin beta-4 should not be relabeled as a TB-500-specific enforcement action. For example, FDA’s January 2026 warning letter to GenoGenix described thymosin beta-4 products as unapproved new drugs and biological products without an approved biologics license application [9]. It also described broader sterile-production and regulatory deficiencies at that facility.

That letter is relevant to the peptide marketplace, but it is not proof that every compounder failed sterility testing or that FDA documented a particular contamination rate for TB-500.

Is there a safe dose or cycle?

No FDA-approved TB-500 dose exists. No human dose-response study has established a therapeutic range, maximum safe dose, loading phase, maintenance phase, injection frequency, or safe duration.

Online schedules such as a fixed number of milligrams one or more times per week are anecdotes or commercial protocols, not validated dosing. Limiting an unstudied regimen to four or six weeks does not make it evidence-based. Combining TB-500 with BPC-157 or other peptides adds another layer of uncertainty because identity, exposure, and interactions may all be unclear.

This page does not provide reconstitution, injection, or cycling instructions because doing so would imply a precision the evidence does not contain.

What to do after suspected exposure or a reaction

If you used a product labeled TB-500:

1. Stop further use until you have medical advice, especially if symptoms occurred.
2. Keep the vial, box, lot number, receipt, photographs, and seller or clinic information. Do not inject from the vial again.
3. Record the stated product, amount, route, dates, co-administered substances, and symptoms.
4. Seek emergency care for trouble breathing, facial or throat swelling, fainting, chest pain, confusion, seizure, or another severe reaction.
5. Seek prompt in-person care for fever, spreading redness, warmth, drainage, worsening injection-site pain, persistent vomiting, severe headache, or feeling markedly unwell.
6. Report the event or product defect to FDA MedWatch; a clinician, pharmacist, patient, or family member can submit a report [10].

There is no standard TB-500 blood level, detox protocol, cancer scan, or monitoring panel. Testing should be driven by the actual symptoms, product information, route, timing, medical history, and examination.

Anti-doping status

The 2026 WADA Prohibited List is in effect. USADA classifies TB-500 as a non-specified substance in the peptide hormones, growth factors, related substances, and mimetics class and states that it is prohibited at all times under rules that adopt the WADA list [11,12].

Detection windows depend on the substance actually present, dose, route, sample, assay, and individual biology. There is no reliable universal “clearance time,” and this page does not provide one. Athletes should use official anti-doping resources rather than forum calculations or seller claims.

What is known vs. what remains unknown